Typhoid Fever Vaccines Market is Anticipated to Witness High Growth Owing to Growing Global Initiative Against Typhoid

Typhoid fever vaccines are immunization vaccines administered to prevent typhoid fever caused by Salmonella Typhi bacteria. Typhoid fever is a life-threatening illness and fatal if not treated. The vaccines available in the market are alive attenuated oral Ty21a vaccine (Vivotif), injectable Typhoid Vi polysaccharide vaccine (Typhim Vi), and conjugate typhoid vaccine (BivVCTC025). The oral Ty21a and injectable Typhim Vi vaccines provide around 70% protection for 2-3 years. However, the conjugated Typhoid vaccine offers long term protection of over 90% for 5 years. Growing immunity initiatives by governments and international organizations to eliminate typhoid as a public health problem are majorly driving the demand for effective typhoid fever vaccines.

The Global Typhoid Fever Vaccines Market is estimated to be valued at US$ 454.2 Bn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the Typhoid Fever Vaccines are Linde Plc, Air Liquide, Engie, Uniper Se, Air Products Inc, Clean Hydrogen System, Cummins Inc., Toshiba Energy Systems & Solutions Corporation, Nel Asa, and Sgh2 Energy.

There is an increase in research initiatives for better vaccines in terms of higher efficacy and longer duration of protection. Organizations like WHO aim to introduce universal access to typhoid conjugate vaccines in endemic countries by 2025.

Major companies are expanding their operations in emerging Asian and African countries owing to a significant disease burden. Strategic partnerships and acquisitions will further aid companies in strengthening global market presence.

Market drivers
Growing incidence of typhoid cases worldwide primarily drives the typhoid fever vaccines market. According to WHO, over 11 million typhoid cases and more than 100,000 deaths are reported globally each year, majority in developing regions lacking proper sanitation and access to clean water. This has triggered global campaigns for effective prevention through vaccination programs.

Strong funding support from international organizations towards large scale vaccination drives in endemic areas also favor market growth. Government initiatives in developing nations to introduce typhoid vaccines in routine immunization programs will further boost revenues.

Market restraints
High costs associated with development and production of typhoid conjugate vaccines remain a major restraint for widespread adoption. Also, the complex multi-dose vaccination schedule acts as a non-compliance challenge. Limited awareness regarding vaccine benefits particularly in remote regions also hinders market growth to some extent.

Segment Analysis
Typhoid Typhoid Fever Vaccines Market Growth can be segmented based on Type into live attenuated vaccine and capsular polysaccharide vaccines. The live attenuated vaccine segment dominates the market as it offers lifelong protection from the disease with just one oral dose. Hence, it is preferred for mass immunization programs in endemic regions.

Global Analysis
Regionally, Asia Pacific accounts for the fastest growth in the typhoid fever vaccines market during the forecast period. This is attributed to large population base, growing awareness regarding preventive healthcare, and increasing government initiatives for immunization in countries like India and China. Many developing nations in Asia are highly endemic for typhoid fever due to poor sanitation and lack of clean drinking water. This makes mass immunization programs crucial in the region for preventing the spread of the disease. North America is expected to be the second largest market owing to rising awareness level and established healthcare infrastructure.

For more insights, read-https://www.pressreleasebulletin.com/typhoid-fever-vaccines-market-trends-size-and-share-analysis/